topic

298 Final analysis of the phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)
Sandra D’Angelo, George Demetri, Brian Van Tine, Mihaela Druta, John Glod, Warren Chow, Naimish Pandya, Aisha Hasan, Victoria Chiou, Jenna Tress, Julie Edwards, Tim Young, Mary Woessner, Alexandra Gyuerdieva, Stefan Zajic, Sophia Goodison, Dejka Araujo

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A182-A183; DOI: 10.1136/jitc-2020-SITC2020.0298
299 Immuno-metabolic signatures of dendritic cells associate with T-cell responses in melanoma patients
Juraj Adamik, Deena Maurer, Paul Munson, Alexis Combes, Philippe Pierre, Matthew Krummel, Rafael Argüello, Lisa Butterfield

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A183; DOI: 10.1136/jitc-2020-SITC2020.0299
340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
Tanya Dorff, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey, Nabil Adra, Mark Salvati, Shirley Poon, Daniel Tan, Gabor Jurida, Hosein Kouros-Mehr, Karim Fizazi, Ben Tran, Lisa Horvath

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A207-A208; DOI: 10.1136/jitc-2020-SITC2020.0340
347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial
Ira Winer, Lucy Gilbert, Ulka Vaishampayan, Seth Rosen, Christopher Hoimes, Jameel Muzaffar, Anna Spreafico, David McDermott, Quincy Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, Valentina Boni, Debora Bruno, Kelly Curtis, Yan Wang, Elizabeth Dorn, Jessicca Rege, Yangchun Du, Ilda Bidollari, Lei Sun, Emily Putiri, Heather Losey, Bruce Dezube, Marc Ernstoff, Vamsidhar Velcheti, James Strauss

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A211-A212; DOI: 10.1136/jitc-2020-SITC2020.0347
349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)
Alain Algazi, William Smith, Timothy Panella, Dong Shin, Marie-Louise Fjaellskog, John Celebi, Alice Drumheller, Jean Campbell, Robert Pierce, Michael Guarino

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A213-A214; DOI: 10.1136/jitc-2020-SITC2020.0349
352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab
Ezra Cohen, Michael Postow, Ryan Sullivan, David Hong, Heather Yeckes-Rodin, Jerry McCarter, Nora Zizlsperger, Jeffery Kutok, Brenda O’Connell, Kara Page, Jennifer Roberts, Halle Zhang, Bartosz Chmielowski

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A214-A215; DOI: 10.1136/jitc-2020-SITC2020.0352
351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009
Kevin Harrington, Ezra Cohen, Lilian Siu, Danny Rischin, Lisa Licitra, Jan Vermorken, Quynh-Thu Le, Makoto Tahara, Jean-Pascal Machiels, Natalyn Hawk, Joy Ge, Behzad Bidadi, Ramona Swaby, Barbara Burtness

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A214; DOI: 10.1136/jitc-2020-SITC2020.0351
353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC
Antonio Jimeno, Sophie Papa, Missak Haigentz, Juan Rodríguez-Moreno, Julian Schardt, Maria Fardis, Friedrich Graf Finckenstein, Rana Fiaz, Guang Chen, Alex Cacovean, Zelanna Goldberg, Ammar Sukari

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A215-A216; DOI: 10.1136/jitc-2020-SITC2020.0353
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
Nina Shah, Alan Tan, Lihua Budde, Craig Hofmeister, Andrew Cowan, Hayder Saeed, Jing Ye, Mitchell Cairo, David Rizzieri, Gregory Orloff, Xue Snow Ge, Zachary Lee, Neha Dixit, Wildaliz Nieves, Mona Vimal, Haijun Ma, Takahiro Miyazaki, Loui Madakamutil, Mario Marcondes, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Krina Patel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A216-A217; DOI: 10.1136/jitc-2020-SITC2020.0355
354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
Sara Pai, Douglas Adkins, Lori Wirth, Christine Chung, Michael Gibson, Ammar Sukari, Francis Worden, Dimitrios Colevas, Nabil Saba, Barbara Burtness, Cristina Rodriguez, Julie Bauman, Bonnie Glisson, Lara Dunn, Anish Suri, Mark Haydock, Steven Quayle, Saso Cemerski, Megan Leader, Jason Brown, Kenneth Pienta, Mary Simcox

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A216; DOI: 10.1136/jitc-2020-SITC2020.0354

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages